IMANISHI Aya

写真a

Affiliation

Graduate School of Medicine  Doctorial Course in Medicine  Bioregulatory Medicine  Department of Neuropsychiatry

Graduating School 【 display / non-display

  •  
    -
    2004.03

    Kumamoto University   Faculty of Medicine   Graduated

Graduate School 【 display / non-display

  •  
    -
    2019.03

    Akita University  Graduate School, Division of Medicine  Doctor's Course  Completed

Campus Career 【 display / non-display

  • 2019.07
    -
    Now

    Akita University   Graduate School of Medicine   Doctorial Course in Medicine   Bioregulatory Medicine   Assistant Professor  

 

Thesis for a degree 【 display / non-display

  • HPVワクチン摂取後の過眠症患者の脳脊髄液中オレキシン濃度は正常である

    Aya Imanishi MD, Takashi Kanbayashi MD, PhD, Yohei Sagawa MD, PhD, Yudai Taniguchi MD, Akari Usumoto MD, Kotaro Yuge MD, Nozomu Kotorii MD, PhD, Tomomi Kinoshita MD, PhD, Toshiaki Hirai MD, PhD, Yuki Omori MD, PhD, Kazuhisa Yoshizawa MD, Tetsuo Shimizu MD, PhD  

    Sleep and Biological Rhythms  17   259 - 261   2019.03

    Domestic Co-author

Published Papers 【 display / non-display

  • Effects of aripiprazole for prolonged nocturnal sleep and delayed sleep phase disorder

    Kanbayashi Takashi, Shimizu Tetsuo, Omori Yuki, Imanishi Aya, Takaki Manabu, Sagawa Youhei, Tsutsui Ko, Takeshima Masahiro, Ono Taisuke, Shiomi Toshiaki

    Neurological Therapeutics ( Japanese Society of Neurological Therapeutics )  34 ( 4 ) 406 - 410   2018

    <p>Delayed sleep phase disorder (DSPD) comprises a persistent or recurrent pattern of sleep disturbances, sleep disruption that leads to insomnia and/or excessive daytime sleepiness, and impaired functioning in social, occupational, or other spheres. Three techniques are typically used to treat DSPD : chronotherapy, phototherapy, and exogenous melatonin administration. Antipsychotics have not been reported in the treatment of DSPD, aripiprazole (APZ), which is a second generation antipsychotic, manifests a novel mechanism of action by serving as a partial agonist of D2 receptors. Depression is reported to be the most common psychopathology associated with DSPD, and APZ is reported to be effective in major depressive disorder as adjunctive therapy. Therefore, we speculated that APZ might be effective to treat DSPD, and we observed how APZ works for the treatment of DSPD.</p><p>Methods : 18 subjects (including 7 women) who are 14–48–year–old (the average is 31.6) were included. The patients were prescribed 0.75–4.5mg APZ at once a day.</p><p>Results : We prescribed 1.5–3.0mg/day of APZ, all subject reduced total sleep time (9.6 +/− 2.3h → 7.8 +/− 2.0h, p=0.03), many cases got up earlier (9.1 +/− 1.9h → 6.7 +/− 1.4h, p=0.005) in the morning and advanced their sleep phase within one week. The sleep onset was not significantly changed (23.5 +/− 2.0h → 22.9 +/− 1.9h, n.s.).</p><p>Conclusion : Low dose of APZ would reduce nocturnal sleep time in the subjects who had prolonged sleep time and DSPD symptoms. The mechanism of action would be dopaminergic up regulation due to dopamine D3 agonistic activity. Since it is difficult for physicians to treat prolonged sleep time and DSPD symptoms, this medication would become a new therapeutic tool for these patients.</p>

    DOI CiNii